 Economic Times | Bayer to appeal against India's patent ruling on Nexavar Business Line The IPAB also came to the conclusion that even though Bayer had obtained a patent for Nexavar in India in 2008, it could not make available the kidney and liver cancer drug on a large scale at an affordable price within the stipulated time. Rejecting ... Patients win over patents Bayer fails to overturn Nexavar compulsory licence in India India board rules against Bayer in cancer drug patent case |
